Evaluating Muscle Aches in a Diabetic Nephropathy Patient on Lisinopril and Simvastatin

QUESTION

A patient with diabetic nephropathy was recently started on lisinopril and simvastatin and comes to your clinic complaining of muscle aches in their calves. You draw a basic metabolic panel, which results in a potassium of 4.5 mEq/L and a serum creatinine of 1.2 mg/dL. You note that the patients baseline serum creatinine was 1 mg/dL on a previously visit. What do you think has occurred?

ANSWER

Evaluating Muscle Aches in a Diabetic Nephropathy Patient on Lisinopril and Simvastatin

Introduction

In clinical practice, it is essential to address and evaluate any new symptoms or concerns presented by patients, especially those undergoing treatment for chronic conditions. In this case, a patient with diabetic nephropathy who was recently initiated on lisinopril and simvastatin has reported muscle aches in their calves. This situation raises questions about potential causes and implications for the patient’s care.

Discussion

The patient’s presentation of muscle aches, specifically in the calves, is a symptom that warrants careful consideration, particularly given their medical history and current medication regimen. When assessing this scenario, several key factors come into play:

Lisinopril and Simvastatin: Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor commonly prescribed to manage hypertension and protect the kidneys in patients with conditions like diabetic nephropathy. Simvastatin, on the other hand, is a statin medication prescribed to lower cholesterol levels. Both medications are generally well-tolerated, but, like all medications, they can have side effects.

2Muscle Aches: Muscle aches can be a side effect of statin medications, like simvastatin. This side effect is known as myalgia. The calf muscles are a common site for such complaints.

Baseline Serum Creatinine Change: The patient’s baseline serum creatinine was 1 mg/dL on a previous visit, but it has now increased to 1.2 mg/dL. This elevation in serum creatinine suggests a change in kidney function. Given the patient’s history of diabetic nephropathy, this change is significant.

Potassium Levels: The patient’s potassium level is within the normal range (4.5 mEq/L). Potassium imbalances can sometimes be associated with muscle issues, but the current level does not indicate hyperkalemia, which would be a more concerning condition.

Considering these factors, it is likely that the muscle aches in the patient’s calves are a side effect of simvastatin, known as myalgia. However, the increase in serum creatinine from the baseline is a concerning finding. It suggests a potential decline in kidney function, possibly due to the use of lisinopril, an ACE inhibitor.

Conclusion

In this scenario, it is essential to address the patient’s symptoms while also carefully monitoring their renal function. The myalgia may be attributed to the simvastatin and can be managed by adjusting the medication regimen or exploring alternative statins. However, the change in serum creatinine, particularly in a patient with diabetic nephropathy, raises concerns about renal health and requires further evaluation and potential adjustments to the treatment plan. Careful consideration and collaboration with the healthcare team will be crucial in ensuring the patient’s well-being and medication management.